NasdaqGS:CRNXPharmaceuticals
What Crinetics Pharmaceuticals (CRNX)'s Orphan Drug Win for Atumelnant Means for Shareholders
Crinetics Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to its drug candidate atumelnant for the treatment of classic congenital adrenal hyperplasia (CAH), following robust positive results from a Phase 2 trial.
This designation recognizes atumelnant as the first and only small molecule ACTH receptor antagonist in clinical development for CAH, offering potential regulatory and market exclusivity incentives.
We'll explore how regulatory incentives tied to Orphan...